You are here: Home:Audio Program Guide: BCU Surgeons 1 | 2006 Audio: BCU Surgeons 1 | 2006     Go to interview with Patrick I Borgen, MD Go to interview with J Michael Dixon, MD Go to interview with John Mackey, MD Go to interview with Clifford Hudis, MD   To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.       Patrick I Borgen, MD Professor of Surgery Weill Medical College of Cornell University Chief, Breast Service, Department of Surgery Memorial Sloan-Kettering Cancer Center New York, New York     Click here to download the entire interview   Track 1 Introduction Track 2 Margin status: Impact on re-excision and local control Track 3 Partial breast irradiation techniques being evaluated in clinical trials Track 4 Postlumpectomy radiation therapy for women over the age of 70 Track 5 Postlumpectomy radiation therapy and hormonal therapy for women with DCIS Track 6 Perspective on the role of aromatase inhibitors in the prevention and adjuvant settings Track 7 Side effects associated with aromatase inhibitors Track 8 Case 1: A patient with a low recurrence score on the Oncotype DX™ assay Track 9 Case 2: A patient with a high recurrence score on the Oncotype DX assay Track 10 Cost effectiveness of the Oncotype DX assay Track 11 Sentinel lymph node biopsy Track 12 Axillary dissection after identification of a positive sentinel node Track 13 Considerations in the selection of patients for nipple-sparing mastectomy Track 14 False-negative rates in sentinel node biopsies Track 15 Surgical volume and outcomes for patients with breast cancer       J Michael Dixon, MD Consultant Surgeon and Senior Lecturer Academic Office Edinburgh Breast Unit Western General Hospital Edinburgh, United Kingdom     Click here to download the entire interview   Track 1 Introduction Track 2 Effect of preoperative aromatase inhibitors on assays of Ki-67 Track 3 Clinical trials of the aromatase inhibitors for DCIS and prevention Track 4 Hormonal therapy options for premenopausal patients with ER-positive disease Track 5 Impact of the aromatase inhibitors on bone mineral density and fracture risk Track 6 Optimal duration of adjuvant endocrine therapy Track 7 Use of genetic profiling in the neoadjuvant setting to predict response to aromatase inhibitors Track 8 Neoadjuvant trials for the development of novel therapeutic agents Track 9 Current status of sentinel lymph node biopsy Track 10 Partial breast irradiation       John Mackey, MD Medical Oncologist, Cross Cancer Institute Associate Professor of Oncology, University of Alberta Chair, Northern Alberta Breast Cancer Program Director, Cancer International Research Group Edmonton, Canada     Click here to download the entire interview   Track 1 Introduction Track 2 Overview of adjuvant aromatase inhibitors in postmenopausal patients Track 3 Efficacy of aromatase inhibitors versus tamoxifen Track 4 Survival benefit of aromatase inhibitors versus tamoxifen Track 5 Endometrial changes associated with tamoxifen Track 6 Impact of aromatase inhibitors on bone density Track 7 Vasomotor symptoms and vascular toxicities associated with tamoxifen Track 8 Arthralgias associated with aromatase inhibitors Track 9 Clinical implications of the adjuvant aromatase inhibitor trials Track 10 Aromatase inhibitors combined with LHRH agonists for premenopausal patients Track 11 Oncotype DX assay and benefits of adjuvant chemotherapy Track 12 Use of the Oncotype DX assay in clinical practice Track 13 Clinical trials of adjuvant trastuzumab for HER2-positive breast cancer Track 14 BCIRG 006: Adjuvant trial of docetaxel/carboplatin/trastuzumab Track 15 TOPO II assay in patients with HER2-positive disease Track 16 Delayed adjuvant trastuzumab for patients with HER2-positive disease Track 17 Combining trastuzumab with dose-dense chemotherapy Track 18 Adjuvant trastuzumab for patients with node-negative breast cancer Track 19 Single-agent trastuzumab as adjuvant therapy for elderly patients       Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division, Memorial Sloan-Kettering Cancer Center New York, New York     Click here to download the entire interview   Track 1 Introduction Track 2 Clinical use of the Oncotype DX assay Track 3 Impact of the Oncotype DX assay on clinical decision-making Track 4 Clinical trials of bevacizumab for breast cancer Track 5 Side effects of bevacizumab Track 6 Incorporation of bevacizumab into adjuvant clinical trials Track 7 Fulvestrant: A “pure” estrogen receptor antagonist Track 8 Using a loading dose of fulvestrant Track 9 Combining fulvestrant with biologic and/or hormonal therapies Track 10 Clinical trial of delayed adjuvant fulvestrant   Search Our Site

Terms and Conditions of Use and General Disclaimer Copyright © 2006 Research To Practice, All Rights Reserved